Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposur...
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
About this item
Full title
Author / Creator
Demel, Ivo , Skopal, David , Šafránková, Eliška , Rozsívalová, Petra , Jindra, Pavel , Šrámek, Jiří , Turková, Adéla , Vydra, Jan , Labská, Klára , Vedrová, Jana , Čerňan, Martin , Szotkowski, Tomáš , Móciková, Heidi , Hynková, Lenka , Šušol, Ondrej , Kováčová, Ingrid , Belada, David and Hájek, Roman
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (...
Alternative Titles
Full title
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10866774
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10866774
Other Identifiers
ISSN
0939-5555,1432-0584
E-ISSN
1432-0584
DOI
10.1007/s00277-023-05572-0
